Offsets |
Aug. 28, 2026
USD ($)
|
|---|---|
| Offset: 1 | |
| Offset Payment: | |
| Offset Claimed | true |
| Rule 457(p) Offset | true |
| Registrant or Filer Name | Spero Therapeutics, Inc. |
| Form or Filing Type | S-3 |
| File Number | 333-277998 |
| Initial Filing Date | Mar. 15, 2024 |
| Fee Offset Claimed | $ 2,744.55 |
| Security Type Associated with Fee Offset Claimed | Unallocated (Universal) Shelf |
| Security Title Associated with Fee Offset Claimed | Unallocated (Universal) Shelf |
| Unsold Aggregate Offering Amount Associated with Fee Offset Claimed | $ 300,000,000.00 |
| Termination / Withdrawal Statement | Pursuant to Rule 457(p) under the Securities Act, the registration fee applicable to the $300,000,000 of securities of the registrant being registered hereby in the amount of $41,430.00 is offset by $33,445.90, which represents the aggregate registration fee previously paid with respect to (a) $300,000,000 of unsold securities under the registrant's Registration Statement on Form S-3 (File No. 333-277998), which was filed with the Securities and Exchange Commission on March 15, 2024 and declared effective by the Commission on March 22, 2024, and (b) $281,405,543 of unsold securities under the registrant's Registration Statement on Form S-3 (File No. 333-254170), which was filed with the Commission on March 11, 2021 and declared effective by the Commission on March 29, 2021. All offerings of the unsold securities associated with the claimed fee offset pursuant to Rule 457(p) have been completed or terminated. |
| Offset: 2 | |
| Offset Payment: | |
| Offset Claimed | true |
| Rule 457(p) Offset | true |
| Registrant or Filer Name | Spero Therapeutics, Inc. |
| Form or Filing Type | S-3 |
| File Number | 333-254170 |
| Initial Filing Date | Mar. 11, 2021 |
| Fee Offset Claimed | $ 30,701.35 |
| Security Type Associated with Fee Offset Claimed | Unallocated (Universal) Shelf |
| Security Title Associated with Fee Offset Claimed | Unallocated (Universal) Shelf |
| Unsold Aggregate Offering Amount Associated with Fee Offset Claimed | $ 281,405,543.00 |
| Termination / Withdrawal Statement | Pursuant to Rule 457(p) under the Securities Act, the registration fee applicable to the $300,000,000 of securities of the registrant being registered hereby in the amount of $41,430.00 is offset by $33,445.90, which represents the aggregate registration fee previously paid with respect to (a) $300,000,000 of unsold securities under the registrant's Registration Statement on Form S-3 (File No. 333-277998), which was filed with the Securities and Exchange Commission on March 15, 2024 and declared effective by the Commission on March 22, 2024, and (b) $281,405,543 of unsold securities under the registrant's Registration Statement on Form S-3 (File No. 333-254170), which was filed with the Commission on March 11, 2021 and declared effective by the Commission on March 29, 2021. All offerings of the unsold securities associated with the claimed fee offset pursuant to Rule 457(p) have been completed or terminated. |
| Offset: 3 | |
| Offset Payment: | |
| Offset Claimed | false |
| Rule 457(p) Offset | true |
| Registrant or Filer Name | Spero Therapeutics, Inc. |
| Form or Filing Type | S-3 |
| File Number | 333-277998 |
| Filing Date | Mar. 15, 2024 |
| Fee Paid with Fee Offset Source | $ 2,744.55 |
| Offset Note | Pursuant to Rule 457(p) under the Securities Act, the registration fee applicable to the $300,000,000 of securities of the registrant being registered hereby in the amount of $41,430.00 is offset by $33,445.90, which represents the aggregate registration fee previously paid with respect to (a) $300,000,000 of unsold securities under the registrant's Registration Statement on Form S-3 (File No. 333-277998), which was filed with the Securities and Exchange Commission on March 15, 2024 and declared effective by the Commission on March 22, 2024, and (b) $281,405,543 of unsold securities under the registrant's Registration Statement on Form S-3 (File No. 333-254170), which was filed with the Commission on March 11, 2021 and declared effective by the Commission on March 29, 2021. All offerings of the unsold securities associated with the claimed fee offset pursuant to Rule 457(p) have been completed or terminated. |
| Offset: 4 | |
| Offset Payment: | |
| Offset Claimed | false |
| Rule 457(p) Offset | true |
| Registrant or Filer Name | Spero Therapeutics, Inc. |
| Form or Filing Type | S-3 |
| File Number | 333-254170 |
| Filing Date | Mar. 11, 2021 |
| Fee Paid with Fee Offset Source | $ 32,730.00 |
| Offset Note | Pursuant to Rule 457(p) under the Securities Act, the registration fee applicable to the $300,000,000 of securities of the registrant being registered hereby in the amount of $41,430.00 is offset by $33,445.90, which represents the aggregate registration fee previously paid with respect to (a) $300,000,000 of unsold securities under the registrant's Registration Statement on Form S-3 (File No. 333-277998), which was filed with the Securities and Exchange Commission on March 15, 2024 and declared effective by the Commission on March 22, 2024, and (b) $281,405,543 of unsold securities under the registrant's Registration Statement on Form S-3 (File No. 333-254170), which was filed with the Commission on March 11, 2021 and declared effective by the Commission on March 29, 2021. All offerings of the unsold securities associated with the claimed fee offset pursuant to Rule 457(p) have been completed or terminated. |